バルター症候群におけるプロスタグランジン合成酵素阻害剤. 免疫反応性プロスタグランジンEの分泌に及ぼす影響
JAMA
|January 9, 1978
まとめ
インドメタシンのような非ステロイド性抗炎症薬 (NSAIDs) は,バルターにおけるプロスタグランジンE (PGE) の分泌を効果的に減少させます.
科学分野:
- ネフロロジーはネフロロジーを用います.
- エンドクリノロジー エンドクリノロジー
- 薬理学 薬理学とは
背景:
- バーター症候群の特徴は,尿中のプロスタグランジンE (iPGE) の分泌の増加である.
- プロスタグランジンは,バルター症候群の病原性において役割を果たします.
研究 の 目的:
- インドメタシン,アスピリン,イブプロフェンの尿中のIPGEに対する効果と,バルター症候群における臨床的症状を比較する.
主な方法:
- 尿中のIPGE濃度が測定されました.
- インドメタシン,アスピリン,イブプロフェンの電解質バランス,レニン活性,クレアチニンクリアランスへの影響は,4人の患者で評価されました.
主要な成果:
- 7人の患者のうち5人は,尿中のIPGEが増加したことを示した.
- インドメタシンは,アスピリンまたはイブプロフェンと比較して,尿中のIPGEの優れた抑制を示しました.
- インドメタシンは,より大きなナトリウムとカリウム保持,血清カリウム増加,血レニン活性低下,およびクレアチニンクリアランスの減少につながった.
結論:
- 尿中のIPGE排出量の減少と,バルター症候群の臨床改善との間に強い相関関係があります.
- プロスタグランジン合成酵素阻害剤は,化学構造に関係なく,バルター症候群の管理に有効です.
関連する概念動画
Drug Elimination by Renal Route: Tubular Secretion
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
Antihypertensive Drugs: Potassium-Sparing Diuretics
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
Renal Drug Excretion: Tubular Secretion
Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...


